Cargando…

Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells

PURPOSE: The toxicity of antiglaucoma medications to ocular surface cells has been evaluated extensively; however, the toxicity to corneal endothelial cells (CECs) remains elusive. Our aim is to evaluate the toxicity of antiglaucoma medications to CECs using an in vitro toxicity assay. METHODS: Prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayaki, Masahiko, Iwasawa, Atsuo, Inoue, Yoichi
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964961/
https://www.ncbi.nlm.nih.gov/pubmed/21060675
http://dx.doi.org/10.2147/OPTH.S13708
_version_ 1782189459473694720
author Ayaki, Masahiko
Iwasawa, Atsuo
Inoue, Yoichi
author_facet Ayaki, Masahiko
Iwasawa, Atsuo
Inoue, Yoichi
author_sort Ayaki, Masahiko
collection PubMed
description PURPOSE: The toxicity of antiglaucoma medications to ocular surface cells has been evaluated extensively; however, the toxicity to corneal endothelial cells (CECs) remains elusive. Our aim is to evaluate the toxicity of antiglaucoma medications to CECs using an in vitro toxicity assay. METHODS: Primary cultures of human (H) CECs derived from eye bank specimens were established. Following exposure of HCECs to test solutions for 10, 30, or 60 minutes, or 48 hours, we measured cell viability using a WST-1 assay. Test solutions were diluted in culture media and included 0.5% Timoptol(®), preservative-free 0.5% timolol maleate, 1% Trusopt(®), preservative-free 1% dorzolamide, Travatan(®), Travatan Z(®), Xalatan(®), and benzalkonium chloride (BAK). To assess cell viability, the value of the test culture well after treatment was expressed as a percentage of that of the control well. Toxicity of each solution was compared using the cell viability score (CVS). RESULTS: After exposure to 10-fold dilutions of test solutions for 48 hours, HCEC viabilities were 48.5% for 0.5% Timoptol, 80.9% for preservative-free 0.5% timolol maleate, 47.0% for 1% Trusopt, 71.7% for preservative-free 1% dorzolamide, 55.5% for Travatan, 88.5% for Travatan Z, and 52.5% for Xalatan. Exposure to test solutions diluted 100-fold or more resulted in HCEC viabilities >80%, with the exception of preservative-free 1% dorzolamide, which resulted in a viability of 72.0% at a dilution of 100-fold. Based on CVS, the order of cell viability was Travatan Z ≥ preservative-free timolol maleate = preservative-free dorzolamide > 0.5% Timoptol = 1% Trusopt > Travatan ≥ Xalatan. Assessment of the combined effect of drug and BAK revealed that latanoprost reduced the toxicity of BAK. CONCLUSION: Antiglaucoma eye drops produced HCEC toxicity that appeared to depend on the presence of BAK. Because dilution of the antiglaucoma solutions resulted in markedly lower HCEC toxicity, HCEC damage due to antiglaucoma medication may occur only in rare cases. The CVS was useful for comparison of the toxicity of the drugs.
format Text
id pubmed-2964961
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-29649612010-11-08 Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells Ayaki, Masahiko Iwasawa, Atsuo Inoue, Yoichi Clin Ophthalmol Original Research PURPOSE: The toxicity of antiglaucoma medications to ocular surface cells has been evaluated extensively; however, the toxicity to corneal endothelial cells (CECs) remains elusive. Our aim is to evaluate the toxicity of antiglaucoma medications to CECs using an in vitro toxicity assay. METHODS: Primary cultures of human (H) CECs derived from eye bank specimens were established. Following exposure of HCECs to test solutions for 10, 30, or 60 minutes, or 48 hours, we measured cell viability using a WST-1 assay. Test solutions were diluted in culture media and included 0.5% Timoptol(®), preservative-free 0.5% timolol maleate, 1% Trusopt(®), preservative-free 1% dorzolamide, Travatan(®), Travatan Z(®), Xalatan(®), and benzalkonium chloride (BAK). To assess cell viability, the value of the test culture well after treatment was expressed as a percentage of that of the control well. Toxicity of each solution was compared using the cell viability score (CVS). RESULTS: After exposure to 10-fold dilutions of test solutions for 48 hours, HCEC viabilities were 48.5% for 0.5% Timoptol, 80.9% for preservative-free 0.5% timolol maleate, 47.0% for 1% Trusopt, 71.7% for preservative-free 1% dorzolamide, 55.5% for Travatan, 88.5% for Travatan Z, and 52.5% for Xalatan. Exposure to test solutions diluted 100-fold or more resulted in HCEC viabilities >80%, with the exception of preservative-free 1% dorzolamide, which resulted in a viability of 72.0% at a dilution of 100-fold. Based on CVS, the order of cell viability was Travatan Z ≥ preservative-free timolol maleate = preservative-free dorzolamide > 0.5% Timoptol = 1% Trusopt > Travatan ≥ Xalatan. Assessment of the combined effect of drug and BAK revealed that latanoprost reduced the toxicity of BAK. CONCLUSION: Antiglaucoma eye drops produced HCEC toxicity that appeared to depend on the presence of BAK. Because dilution of the antiglaucoma solutions resulted in markedly lower HCEC toxicity, HCEC damage due to antiglaucoma medication may occur only in rare cases. The CVS was useful for comparison of the toxicity of the drugs. Dove Medical Press 2010-10-21 2010 /pmc/articles/PMC2964961/ /pubmed/21060675 http://dx.doi.org/10.2147/OPTH.S13708 Text en © 2010 Ayaki et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Ayaki, Masahiko
Iwasawa, Atsuo
Inoue, Yoichi
Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells
title Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells
title_full Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells
title_fullStr Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells
title_full_unstemmed Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells
title_short Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells
title_sort toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964961/
https://www.ncbi.nlm.nih.gov/pubmed/21060675
http://dx.doi.org/10.2147/OPTH.S13708
work_keys_str_mv AT ayakimasahiko toxicityofantiglaucomadrugswithandwithoutbenzalkoniumchloridetoculturedhumancornealendothelialcells
AT iwasawaatsuo toxicityofantiglaucomadrugswithandwithoutbenzalkoniumchloridetoculturedhumancornealendothelialcells
AT inoueyoichi toxicityofantiglaucomadrugswithandwithoutbenzalkoniumchloridetoculturedhumancornealendothelialcells